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Hypertension is the most common cardiovascular disease, afflicting >30% of adults 1 . The cause of hypertension in most individuals remains unknown 2, 3 , suggesting that additional contributing factors have yet to be discovered. Corin is a serine protease that activates the natriuretic peptides, thereby regulating blood pressure 4 . It is synthesized as a zymogen that is activated by proteolytic cleavage. CORIN variants and mutations impairing corin activation have been identified in people with hypertension and pre-eclampsia [5] [6] [7] [8] [9] . To date, however, the identity of the protease that activates corin remains elusive. Here we show that proprotein convertase subtilisin/kexin-6 (PCSK6, also named PACE4; ref. 10) cleaves and activates corin. In cultured cells, we found that corin activation was inhibited by inhibitors of PCSK family proteases and by small interfering RNAs blocking PCSK6 expression. Conversely, PCSK6 overexpression enhanced corin activation. In addition, purified PCSK6 cleaved wild-type corin but not the R801A variant that lacks the conserved activation site. Pcsk6-knockout mice developed salt-sensitive hypertension, and corin activation and pro-atrial natriuretic peptide processing activity were undetectable in these mice. Moreover, we found that CORIN variants in individuals with hypertension and pre-eclampsia were defective in PCSK6-mediated activation. We also identified a PCSK6 mutation that impaired corin activation activity in a hypertensive patient. Our results indicate that PCSK6 is the long-sought corin activator and is important for sodium homeostasis and normal blood pressure.
Maintenance of normal blood pressure is of fundamental importance in health. Hypertension is a major risk factor for leading cardiovascular diseases such as myocardial infarction, heart failure and stroke. Mechanistically, hypertension reflects inadequate control of salt and body fluid balance 11, 12 . Consistent with this idea, genetic mutations that alter sodium homeostasis have been identified in subgroups of hypertensive patients 2, 3, 13 . Given the high prevalence of hypertension in general populations 1 , it is probable that more genes involved in sodium homeostasis remain unidentified.
Atrial natriuretic peptide (ANP) is a hormone essential for sodium homeostasis 14 . Common genetic variants in the NPPA gene locus (encoding ANP) are associated with circulating natriuretic peptide and blood pressure levels in general populations 15 . ANP variants have been reported in hypertensive patients [16] [17] [18] [19] . In cardiomyocytes, the precursor form of ANP, pro-ANP, is cleaved by corin, a transmembrane serine protease, to produce ANP 4 . A trypsinlike enzyme, corin is synthesized as an inactive zymogen that is activated by cleavage at a conserved site between Arg801 and Ile802 (ref. 20) (Fig. 1a) . Activated corin may undergo autocleavage and a disintegrin and metalloprotease (ADAM)-mediated shedding 21 (Fig. 1a) , which reduces corin activity on the cell surface. The enzyme responsible for activation of the corin zymogen has not been identified.
To understand how corin is activated, we expressed wild-type (WT) corin and either of two inactive corin variants in HEK293 human embryonic kidney cells (Fig. 1b) or mouse HL-1 cardiomyocytes (Supplementary Fig. 1 ). The inactivated variants were R801A, in which the activation site is abolished, and S985A, in which the catalytic serine is mutated (Fig. 1a) . On western blots, corin zymogen migrated at ~170-200 kDa. An ~40-kDa band, representing the activated corin protease domain fragment (Corin-p), was detected in cells expressing WT corin. This band was present under reducing but not non-reducing conditions owing to the presence of a disulfide bond that connects the cleaved fragment to the propeptide (Fig. 1a) . The ~40-kDa band was absent in cells expressing the R801A variant but was present in cells expressing the S985A variant, indicating that, in both HEK293 and HL-1 cells, corin is activated specifically at Arg801 by an unknown enzyme or enzymes.
We next tested different protease inhibitors for their effects on corin activation in transfected HEK293 cells. Western blot analysis showed that benzamidine (serine protease inhibitor) and dec-RVKR-cmk (PCSK protease inhibitor), but not GM6001 (metalloproteinase inhibitor) or ALLM (N-acetyl-leucyl-leucyl-methionine; cysteine protease inhibitor), inhibited corin activation, as indicated by reduced levels of the ~40-kDa band and increased levels of an ~190-kDa zymogen band ( Fig. 1c and Supplementary Fig. 2 ). Trypsin digestion studies showed that the ~190-kDa band represents corin zymogen on the cell surface (Supplementary Fig. 3 ). These results suggest that one or more PCSK family proteases activate corin in these cells. Consistent with this hypothesis, the corin activation cleavage sequence is RMNKR↓, and PCSKs are known to cleave following two basic residues 10, 22 .
There are nine PCSK family members 10, 22 . We transfected plasmids encoding each of the PCSKs (PCSK1-PCSK9) into HEK293 cells expressing human corin. Western blot analysis showed that PCSK6 expression enhanced corin activation, as indicated by loss of the corin zymogen band (Fig. 1d and Supplementary Figs. 4 and 5) , suggesting that PCSK6 is a corin activator. By RT-PCR, we detected PCSK6 mRNA in HEK293 and HL-1 cells as well as in mouse and human hearts, where corin normally is produced 20 ( Supplementary  Fig. 6 ). These results are consistent with a previous report of PCSK6 expression in cardiomyocytes 23 . Using small interfering RNAs (siRNAs) targeting either human or mouse PCSK6 genes, we showed that blocking PCSK6 expression inhibited corin activation cleavage in transfected HEK293 and HL-1 cells, whereas scrambled siRNAs or siRNAs targeting PCSK1, PCSK3 or PCSK5 had no such effects under similar conditions (Fig. 1e-j and Supplementary Fig. 7) .
We next examined the cellular mechanism by which PCSK6 activates corin. In corin-expressing cells treated with brefeldin A (BFA), which blocks protein endoplasmic reticulum (ER) trafficking, corin cell surface expression and zymogen activation were inhibited (Fig. 2a,b) , indicating that corin is not activated in the ER. We then tested monensin, a Golgi-perturbing agent that blocks the secretory pathway. Monensin did not prevent corin cell surface expression, but it did inhibit corin activation, as indicated by the lack of the ~40-kDa band (Fig. 2c,d ). As expected, monensin reduced the levels of PCSK6, which is secreted via the secretory pathway 10 , in the conditioned medium but not in the cell lysate (Fig. 2e) . These data suggest a model in which PCSK6 and corin traffic via separate intracellular pathways to the cell surface, where PCSK6 activates corin (Fig. 2f) . This model is consistent with the results from a trypsin digestion experiment (Supplementary Fig. 3 ), in which activated corin was detected on the cell surface but not intracellularly.
To further test this hypothesis, we added conditioned medium containing PCSK6 to HEK293 cells expressing corin. Increased corin activation was detected with increasing amounts of PCSK6 in the conditioned medium (Fig. 2g,h ). Such activation was not observed if the conditioned medium was first immunodepleted using a PCSK6-specific antibody (Fig. 2i) . We also showed that purified recombinant PCSK6 (Supplementary Fig. 8 ) activated WT corin but not the R801A variant on HEK293 cells (Fig. 2j) . These results support a cellular mechanism in which corin is activated only after reaching the cell surface, thereby preventing proteolytic activity inside the cell.
On the basis of these in vitro studies indicating that PCSK6 acts as a corin activator, we tested whether PCSK6 can activate corin in vivo using WT and Pcsk6-knockout (KO) mouse hearts. On western blots, three corin bands of ~190, ~160 and ~110 kDa were detected in Pcsk6-KO mouse hearts, whereas only the ~160-and ~110-kDa bands, C o n t r o l B e n z G . In e, non-adjacent lanes from the same western blot were used, as indicated.
npg l e t t e r S at lower levels than in the KO hearts, were detected in WT hearts (Fig. 3a,b) . As a negative control, no bands were detected in Corin-KO hearts (Fig. 3a,b) . In Pcsk6-KO hearts, high levels of the ~190-kDa band-which, as shown in trypsin and glycosidase digestion experiments, represents the cell surface corin zymogen ( Supplementary  Figs. 3 and 9 )-indicated impaired corin activation. In agreement with this result, we found little pro-ANP processing activity in cell membranes from Pcsk6-or Corin-KO hearts as compared with those from WT mouse hearts (Fig. 3c,d) . As a control, we detected corin activity in cell membranes from corin-expressing, but not parental, HEK293 cells (Fig. 3c) . Pro-ANP levels were high in Pcsk6-and Corin-KO hearts compared with WT control hearts ( Fig. 3e-g ). In contrast, pro-BNP levels were similar in WT, Pcsk6-KO and Corin-KO mouse hearts (Supplementary Fig. 10 ). As assessed by ELISA, plasma pro-ANP and/or ANP levels in WT, Pcsk6-and Corin-KO mice were below the linear detection limit. To circumvent this problem, we measured plasma natriuretic peptide activities in a cell-based cGMP stimulation assay. We detected reduced natriuretic peptide activities in plasma samples from Pcsk6-and Corin-KO mice as compared with WT mice (Fig. 3h) . These results indicate that PCSK6 is a primary corin activator in vivo and that lack of PCSK6 prevents corin activation and pro-ANP processing. In mice, corin deficiency impairs sodium homeostasis, causing salt-sensitive hypertension 24 . If PCSK6 deficiency prevented corin activation in vivo, we would expect to observe a similar hypertensive phenotype in Pcsk6-KO mice. Indeed, Pcsk6-KO mice were hypertensive on a normal-salt (0.3% NaCl) diet (Fig. 3i) . The hypertensive phenotype was exacerbated when the mice were placed on high-salt (4% and 8% NaCl) diets (Fig. 3i) , indicating that PCSK6-mediated corin activation is essential for sodium homeostasis and normal blood pressure in mice and that PCSK6 deficiency may cause salt-sensitive hypertension in humans. In histological analyses, cardiac hypertrophy was detected in Corin-KO but, surprisingly, not in Pcsk6-KO mice (Supplementary Fig. 11 ). Moreover, echocardiography showed normal cardiac function in Pcsk6-and Corin-KO mice (Supplementary Figs. 12  and 13) . By electron microscopy, sarcomeric structures were similar in WT and Pcsk6-KO mice, whereas they had a thicker appearance in Corin-KO mice (Supplementary Fig. 14) . These results suggest that PCSK6 may have other substrates (for example, transforming growth factor beta (TGF-β; ref. 25) ) and that the action of PCSK6 on these substrates may promote tissue remodeling and cardiac hypertrophy.
In humans, a CORIN variant allele encoding a protein with two amino acid substitutions, T555I and Q568P, has been identified in African-Americans with hypertension and heart disease 7, 8 . The variant protein encoded by this allele is defective in pro-ANP processing in vitro and in vivo 9, 26 . Activation of the corin variant containing both the T555I and Q568P amino acid substitutions, but not corin variants containing either T555I or Q568P, is markedly reduced 9 . We found that PCSK6 was able to cleave WT corin and variants containing either T555I or Q568P, but not the variant containing both T555I and Q568P (Fig. 4a,b and Supplementary Fig. 15a) .
Recently, corin was found to act in the uterus to prevent pregnancyinduced hypertension 5 . CORIN mutations encoding the K317E, S472G and R539C corin variants have been identified in patients with preeclampsia and hypertension, and these variants have impaired activation and reduced pro-ANP processing activity 5, 6 . Biochemical studies showed that the S472G variant is retained in the ER, whereas the K317E and R539C variants are present on the cell surface 6, 27 . By western blot analysis, we found that the K317E, S472G and R539C variants showed 61%, 1% and 38%, respectively, of the PCSK6-mediated activation seen with WT corin (Fig. 4a,c and Supplementary Fig. 15b ),
indicating that these natural corin variants are defective in PCSK6-mediated activation. Retention of the S472G variant in the ER would be expected to prevent its trafficking to the cell surface and hence its l e t t e r S zymogen activation. In trypsin-like proteases, domain structures in the propeptide are known to interact with their activators 28 . In the case of the protease TMPRSS3, for example, mutations in its propeptide prevent zymogen activation, causing deafness 29 . Thus, our results may provide insights into the biochemical basis of defective corin function in people with hypertension.
We next sequenced the PCSK6 gene in 100 hypertensive individuals and identified a mutation causing an Asp282Asn (D282N) change in the PCSK6 catalytic domain in one such person (Fig. 4d,e  and Supplementary Table 1) . This mutation was not found in any of 118 normal control individuals. In transfected HEK293 cells, the D282N variant was associated with reduced corin-activating activity and a dominant-negative effect on endogenous PCSK6 activity (Fig. 4f,g ). Compared with that of WT PCSK6, secretion of the D282N variant was impaired (Fig. 4h) . When HEK293 cells expressing WT corin were treated with conditioned medium containing increasing amounts of D282N protein, corin activation was dose-dependently increased (Fig. 4i,j) . When the D282N variant was co-transfected with WT PCSK6, the D282N variant exhibited a dominant-negative effect, inhibiting WT PCSK6 secretion into the culture medium and reducing corin activation in the transfected cells ( Supplementary  Fig. 16 ). These results are consistent with the cellular model in which PCSK6 activates corin on the cell surface but not intracellularly (Fig. 2f) . It remains to be determined whether the PCSK6 mutation we identified impairs corin activation and contributes to hypertension in humans.
Corin-mediated natriuretic peptide activation is essential for normal blood pressure and cardiac function 24, 30 . In individuals with heart failure, levels of unprocessed natriuretic peptides are high, indicating that corin activity is a rate-limiting factor in failing hearts [31] [32] [33] . A recent study showed that corin overexpression improves cardiac function in a mouse model of heart failure 34 . PCSK6 has been reported to process growth factors and metalloproteinases 10, 25 . Here we show that PCSK6 also acts as a primary corin activator in the heart, and that PCSK6 deficiency causes salt-sensitive hypertension in mice. Consistent with these findings, the PCSK6 gene was previously linked to hypertension in humans 35 . Among PCSK family members, PCSK9 has been identified as a key regulator that binds to the low-density lipoprotein (LDL) receptor and promotes the receptor's degradation [36] [37] [38] . PCSK9 inhibitors are being developed as therapeutic agents to lower LDL cholesterol levels [38] [39] [40] . Our findings from this study provide new evidence that PCSK family members may be exploited therapeutically to treat hypertension and heart disease.
METHOdS
Methods and any associated references are available in the online version of the paper. Effects of BFA and monensin. To examine the cellular mechanism of PCSK6-mediated corin activation, we tested cell organelle-disturbing agents BFA and monensin, which block protein trafficking in the ER and the secretory pathway, respectively 45 . HEK293 cells expressing corin were treated with BFA (0.5 and 1 µM) (Sigma, B7651) or monensin (0.2 and 2 µM) (Sigma, M5273) at 37 °C for 24-48 h. The cells were lysed in the lysis buffer and corin protein on the cell surface and in cell lysate was analyzed by western blotting.
Effect of protease inhibitors on corin activation cleavage. To identify the corin activator, we examined corin activation cleavage in HEK293 and HL-1 cells expressing corin in the presence of protease inhibitors including benzamidine (5 mM) (Sigma, 434760), GM6001 (50 µM) (Enzo Life Sciences, BML-EI300), dec-RVKR-cmk (20 µM) (Enzo Life Sciences, ALX-260-022) and ALLM (N-acetyl-leucyl-leucyl-methionine, 50 µM) (Santa Cruz, sc-201268) (ref. 41 ). The inhibitors were added to the cells in separate wells. After 24 h, cell lysates were prepared and corin protein was analyzed by western blotting, as described above.
PCSK6 mRNA expression. Total RNAs were isolated from HEK293 and HL-1 cells and human and mouse hearts using TRIzol reagents (Invitrogen). First-strand cDNAs were synthesized using the SuperScript III kit (Invitrogen).
Human and mouse PCSK6 mRNAs were amplified by RT-PCR with specific oligonucleotide primers. Negative controls included reactions without cDNA templates. PCR products were analyzed on 1.3% (wt/vol) agarose gels followed by ethidium bromide staining.
PCSK6 gene knockdown. On-TARGET plus SMARTpool siRNAs against human PCSK6 (LU-005983-00-0002) or mouse Pcsk6 (LU-059121-01-0002) were obtained from Thermo Scientific. Each siRNA pool contained siRNAs targeting four different sites in the gene. The siRNAs were transfected into HEK293 or HL-1 cells expressing recombinant corin. Non-targeting scrambled siRNAs were used as negative controls. After 48-68 h at 37 °C, corin expression on the cell surface and in cell lysate was analyzed by western blotting. PCSK6 expression in siRNA-treated cells was verified by western blotting. In parallel, siRNAs targeting human PCSK1, PCSK3 and PCSK5 genes also were transfected into HEK293-corin cells. Corin activation in the transfected cells was examined by western analysis.
Corin activation in the presence of PCSK6 conditioned medium. Conditioned medium (CM) from HEK293 cells stably expressing PCSK6 was collected and centrifuged to remove cellular debris. Increasing volumes of CM were added to corin-expressing HEK293 cells that were cultured in the presence of monensin (2 µM). After 2 h at 37 °C, the cells were lysed. Corin protein in the cell lysate was analyzed by western blotting. To deplete PCSK6 from the CM, an anti-PCSK6 antibody (Sigma, SAB2101751, 5 µg) or control normal IgG (Sigma, I5006, 5 µg) was incubated with 2 ml of CM from PCSK6-transfected cells for 2 h. After immunoprecipitation, the supernatant was collected and added to the HEK293-corin cells. Corin activation was examined by western blot analysis, as described above.
Mice. Corin-KO mice have previously been described 24, 30 . Pcsk6-KO mice were generated as previously 25 and were backcrossed onto C57BL/6 background for at least ten generations 46 . No apparent cardiac defects were observed in adult Pcsk6-KO mice, as indicated in Supplementary Figures 11-14 . Male WT, Corin-KO and Pcsk6-KO mice (4-6 months old) were used for tissue collection and blood pressure measurements. All procedures were carried out in accordance with US National Institutes of Health (NIH) guidelines for the ethical treatment and handling of animals in research, and approved by the Cleveland Clinic Institutional Animal Care and Use Committee. The sample size for mouse studies was determined on the basis of our previous experience with these mouse models. No randomization was used, and the investigators who performed the experiments were not blinded to mouse genotypes.
Corin, PCSK6, pro-ANP and pro-BNP protein expression in mouse hearts. Mouse heart tissue homogenates were prepared in a buffer with or without a protease inhibitor cocktail 32 . Corin, PCSK6, pro-ANP and pro-BNP protein levels were analyzed by western blotting using antibodies against corin made in our laboratory 5 , PCSK6 (Abcam, ab151562), pro-ANP (Abcam, ab126149) and pro-BNP (Santa Cruz, sc-67455), respectively. Glycosidase digestion. Transfected HEK293 cells expressing human or mouse corin were lysed in the lysis buffer described above. Mouse heart membrane fractions were prepared using hearts from WT and Pcsk6-KO mice, as described previously 32 . The cell lysate (25 µg) and membrane proteins (40 µg) were incubated in a deglycosylation denaturing buffer (New England BioLabs) at 100 °C for 10 min. Peptide N-glycosidase F (PNGase F) (1 unit) or endoglycosidase H (Endo H) (1 unit) (New England BioLabs) was added to the protein mixture and incubated at 37 °C for 2 h 47 . Corin proteins were analyzed by SDS-PAGE and western blotting 44 .
Pro-ANP processing assay. Membrane fractions from hearts were extracted by ultracentrifugation, as described previously 32 . The membrane pellets were resuspended in an NP-40 buffer 32 . Conditioned medium from stable HEK293 cells expressing human pro-ANP was incubated with increasing amounts of heart membrane proteins. The conversion of pro-ANP to ANP was analyzed by western blotting 32 . The percentage of pro-ANP to ANP conversion was quantified by densitometric analysis of western blots, as described previously 44 . npg
